Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 10/20 | 0.39 |
| ▸ | PTGER2 | P43116 | 9/20 | 0.39 |
| ▸ | PTGER3 | P43115 | 7/20 | 0.39 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.35 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.35 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.35 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.34 |
| ▸ | FDPS | P14324 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | PTGFR | P43088 | 2/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5852426 | 0.99 | PTGER4 (0.38) | PTGER4PTGER2PTGER3S1PR2S1PR4 | |
| SCHEMBL11727538 | 0.83 | PTGER4 (0.57) | PTGER4PTGER2PTGER3PTGFRTBXA2R | |
| SCHEMBL11727526 | 0.83 | PTGER4 (0.57) | PTGER4PTGER2PTGER3PTGFRTBXA2R | |
| SCHEMBL5852489 | 0.83 | PTGER4 (0.57) | PTGER4PTGER2PTGER3PTGFRTBXA2R | |
| SCHEMBL11727535 | 0.83 | PTGER4 (0.57) | PTGER4PTGER2PTGER3PTGFRTBXA2R | |
| SCHEMBL11732308 | 0.80 | PTGER2 (0.45) | PTGER4PTGER2PTGER3PTGFRTBXA2R | |
| SCHEMBL11732298 | 0.80 | PTGER2 (0.45) | PTGER4PTGER2PTGER3PTGFRTBXA2R | |
| SCHEMBL11727905 | 0.80 | PTGER2 (0.45) | PTGER4PTGER2PTGER3PTGFRTBXA2R | |
| SCHEMBL11731194 | 0.78 | PTGER4 (0.49) | PTGER4PTGER2PTGER3POLBPTGFR | |
| SCHEMBL11178691 | 0.76 | PTGER4 (0.59) | PTGER4PTGER2PTGER3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115659-B2 | Method of treating a condition by administering a prostaglandin derivative | THE PROCTER & GAMBLE COMPANY (US) | 2006-10-03 | — | — | US | disclosed |
| US-7074942-B2 | 2-decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use | THE PROCTER & GAMBLE COMPANY (US) | 2006-07-11 | — | — | US | disclosed |
| US-20050124588-A1 | 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use | THE PROCTER & GAMBLE COMAPANY | 2005-06-09 | — | — | US | disclosed |
| US-20050124587-A1 | 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use | THE PROCTER & GAMBLE COMPANY | 2005-06-09 | — | — | US | disclosed |
| US-6894175-B1 | 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use | THE PROCTER & GAMBLE COMPANY (US) | 2005-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124588-A1 | 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use | PTGDR2, PTGES2, PTGS2 | PTGER4 36/4885PTGER2 5/4885PTGER3 61/4885 |
| US-20050124587-A1 | 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use | PTGES2, PTGES, PTGS2 | PTGER4 32/4885PTGER2 5/4885PTGER3 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.